Clinical Trials
9 trialsNCT06417892 2026-04-21
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
NCT06714903 2024-12-04
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
The First Hospital of Jilin University
Recruiting
NCT06470178 2024-06-24
A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
Wuhan University
Not yet recruiting
NCT06202417 2024-01-11
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Fudan University
Completed
NCT06102785 2023-10-26
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Recruiting
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT05993702 2023-08-15
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
China Medical University, China
Unknown
NCT05635149 2022-12-02
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unknown
NCT04431791 2020-06-16
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
Peking University
Unknown